N-((1r,4r)-4-hydroxycyclohexyl)-3-phenyl-1H-pyrazole-5-carboxamide

ID: ALA5285962

Max Phase: Preclinical

Molecular Formula: C16H19N3O2

Molecular Weight: 285.35

Names and Identifiers

Canonical SMILES:  O=C(N[C@H]1CC[C@H](O)CC1)c1cc(-c2ccccc2)n[nH]1

Standard InChI:  InChI=1S/C16H19N3O2/c20-13-8-6-12(7-9-13)17-16(21)15-10-14(18-19-15)11-4-2-1-3-5-11/h1-5,10,12-13,20H,6-9H2,(H,17,21)(H,18,19)/t12-,13-

Standard InChI Key:  AQDRWHAJRPREQV-JOCQHMNTSA-N

Molfile:  

 
     RDKit          2D

 21 23  0  0  0  0  0  0  0  0999 V2000
    3.9924   -0.9634    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.1674   -0.9634    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7550   -1.6779    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9300   -1.6779    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5174   -0.9634    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9299   -0.2489    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7549   -0.2489    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6924   -0.9634    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.2800   -0.2489    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6924    0.4654    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5449   -0.2489    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9575   -0.9635    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7646   -0.7919    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8509    0.0286    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0971    0.3642    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5658    0.4413    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2805    0.0289    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9924    0.4408    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9924    1.2661    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2823    1.6779    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5658    1.2699    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  1
  3  2  1  0
  4  3  1  0
  5  4  1  0
  6  5  1  0
  7  6  1  0
  2  7  1  0
  5  8  1  6
  9  8  1  0
  9 10  2  0
 11  9  1  0
 11 12  1  0
 12 13  1  0
 13 14  2  0
 15 14  1  0
 15 11  2  0
 16 14  1  0
 17 16  2  0
 18 17  1  0
 19 18  2  0
 20 19  1  0
 21 20  2  0
 16 21  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA5285962

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 285.35

Molecular Weight (Monoisotopic): 285.1477

AlogP: 2.11

#Rotatable Bonds: 3

Polar Surface Area: 78.01

Molecular Species: NEUTRAL

HBA: 3

HBD: 3

#RO5 Violations: ┄

HBA (Lipinski): 5

HBD (Lipinski): 3

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 11.25

CX Basic pKa: 1.65

CX LogP: 1.72

CX LogD: 1.72

Aromatic Rings: 2

Heavy Atoms: 21

QED Weighted: 0.81

Np Likeness Score: -1.27

References

1. Jo M, Koizumi K, Suzuki M, Kanayama D, Watanabe Y, Gouda H, Mori H, Mizuguchi M, Obita T, Nabeshima Y, Toyooka N, Okada T..  (2023)  Design, synthesis, structure-activity relationship studies, and evaluation of novel GLS1 inhibitors.,  87  [PMID:37011768] [10.1016/j.bmcl.2023.129266]

Source

Source(1):

• Scientific Literature